Biomedical Research

Journal Banner

Study on the application of immune index such as CT enhanced cyclooxygenase 2, etc. in the diagnosis of lung cancer

Background: Because of the angiogenic process of malignant tumours, there was significant difference between lung cancer blood supply and benign lesion. The Vascular Endothelial Growth Factor (VEGF) and Cyclooxygenase-2 (COX-2) is associated with the progression and poor prognosis of lung cancer. The aim of the study was to assess the correlation between the expression of COX-2, VEGF and Micro Vessel Density (MVD) and CT enhanced performance in lung cancer.

Methods: 25 cases of pathologically confirmed lung cancer and 35 cases of benign lung lesions were conducted by CT enhanced scanning, and the PV method was used for immunohistochemical analysis in the pathological specimen as well as the relationship between expression level of COX-2, VEGF, MVD and CT enhanced peak, histological type, clinical stage, lymph node metastasis and differentiation degree in lung cancer.

Results: Expression levels of COX-2, VEGF and MVD in the lung cancer group and control group; expression level of COX-2, VEGF and MVD is closely related to histological type, clinical stage, lymph node metastasis and CT enhanced peak in lung cancer, and has nothing to do with the degree of differentiation of lung cancer.

Conclusion: Our results showed that the expression of COX-2, VEGF and MVD in lung cancer is positively related to the peak value of CT enhancement, which indicated that CT enhancement can provide a non-invasive and non-invasive method for the diagnosis and evaluation of lung cancer.

Author(s): Jiang Chang, Xueying Zhang, Jinping Zhang, Fushan Chang, Xueying Zhang